Analysts believe while the deal is positive, Cipla share price is unlikely to see fresh run up given the rise in the ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...

Brokerage firm Nuvama Institutional Equities believes Cipla, with its strong field force and distribution network, could ...

On October 23, Lilly and Mumbai-based Cipla announced a joint agreement to distribute and promote tirzepatide under the brand ...

Eli Lilly's launch of Mounjaro in India in March 2025 was the first step of Tirzepatide in the country. In June 2025, the ...

Eli Lilly's rival Novo Nordisk plans to retail both Ozempic and Wegovy in India as diabetes and weight-loss drugs, respectively.| Business News ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Cipla has partnered with Eli Lilly and Company (India) to distribute & promote Tirzepatide in India under a second brand name, Yurpeak, aiming to expand access to innovative treatments for chronic ...

Cipla-Eli Lilly partner to distribute Tirzepatide under the Yurpeak brand in India ・Tirzepatide is used to manage type 2 ...

In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...

US-based pharma giant Eli Lilly’s blockbuster weight-loss drug, Mounjaro, is set to expand its reach across India through a ...